



303 VINTAGE PARK DRIVE
FOSTER CITY, CA 94404
Tel. 877-840-8662 (TOMA)
Fax. 800-923-8870
www.tomabio.com

TOMA OS-SEQ™ CANCER ASSAY

Comprehensive detection of cancer somatic variants

The TOMA OS-Seq™ Cancer Assay is a beginning-to-end cancer gene variant profiling assay that delivers a complete, comprehensive solution for cancerous somatic variant detection. The assay evaluates genes for all types of sequence variants, including copy number alterations (CNAs). Its simplified, highly efficient library preparation method reduces sample loss, minimizes dependence on PCR, and reduces preparation time.

Using the TOMA OS-Seq™ Cancer Assay, researchers can quickly interrogate precious tumor samples from FFPE samples using less material while maintaining excellent data quality. Final results are generated in Stratus™, our easy-to-use, cloud-based genomic data analysis tool that delivers the latest methods in somatic variant analysis without expensive computing infrastructure.


| | TOMA OS-SEQ | OTHER COMMERCIAL REAGENTS | TOMA OS-SEQ ADVANTAGE |
|------------------------------------|---|---|---|
| CANCER GENE COVERAGE | Comprehensive – complete sequencing of every exon interrogated | Limited – “Hot Spot” methods exclude up to 90% of each gene and are not able to report all variant types | Detects all mutation types: single nucleotide variations, short indels, and copy number alterations |
| SAMPLE - EFFICIENT | Highly – accepts DNA inputs as low as 10 ng from FFPE (formalin-fixed paraffin embedded tissue) | Requires large quantities of DNA input – exhausts precious oncology patient samples - high rate of rejection (quantity not sufficient QNS) | Preserves precious patient samples – accept DNA inputs as low as 10ng |
| SENSITIVE VARIANT DETECTION | Complete – High sensitivity for all variant types, down to 2% for single nucleotide variants (SNVs) and 94% concordance to FISH for copy number (CNAs) | False Negatives – misses majority of copy number alterations, the largest class of actionable genomic alterations in cancer | Dramatically increases clinically significant findings |
| EFFICIENCY | High Yield – from ultra efficient adaptor ligation | Low Yield – highly dependant upon PCR to generate sufficient library for sequencing | Highly efficient library preparation method preserves precious sample |
| PCR USED IN DNA PREPARATION | Minimal – library preparation method only amplifies targets of interest; eliminates whole genome PCR | High – amplifies “whole genome” PCR creating artifacts and errors, reducing specificity and causing analysis issues | No “whole genome,” PCR dramatically reduces errors common to other methods |
| SEQUENCING DEPTH | 500X – up to 6 concurrent samples on an Illumina MiSeq | LOW – misses key mutations and significantly increases false negatives | Minimizes false negatives |
| ANALYSIS | Simple – TOMA Stratus™ easy, accurate calling of somatic alterations, including CNAs | None – limited assay specific bioinformatics; not designed for somatic alteration detection | Simple – Stratus provides the easiest, high accuracy variant calls |
| TIMING | Fast – DNA library complete in 16 hours (3 hrs hands on time) | Slow – takes 2-3 days | Generates a sequencing library in a single day |

For Research Use Only. Not for use in diagnostic procedures.



| TOMA OS-SEQ™ 131 CANCER GENE PANEL | | | | | | | |
|------------------------------------|--------|--------|-------|--------|--------|---------|--------|
| ABL1 | BRCA1 | CDKN2B | FGFR1 | KIT | NBN | PTPN11 | SYK |
| ABL2 | BRCA2 | CEBPA | FGFR2 | KRAS | NF1 | RAD50 | TERT |
| AKT1 | BTK | CSF1R | FGFR3 | MAP2K1 | NFE2L2 | RB1 | TET2 |
| AKT3 | CALR | CTNNB1 | FGFR4 | MAP2K2 | NOTCH1 | RET | TP53 |
| ALK | CCND1 | CYP2D6 | FLT3 | MAPK1 | NPM1 | RICTOR | TPMT |
| APC | CCND2 | DDR2 | GNA11 | MCL1 | NRAS | RNF43 | TSC1 |
| AR | CCND3 | DNMT3A | GNAQ | MDM2 | NTRK1 | ROS1 | TSC2 |
| ARAF | CD274 | DPYD | GNAS | MET | NTRK2 | RPTOR | U2AF1 |
| ASXL1 | CDH1 | EGFR | H3F3A | MLH1 | NTRK3 | RUNX1 | UGT1A1 |
| ATM | CDK12 | EMSY | HNF1A | MPL | PALB2 | SF3B1 | VEGFA |
| ATR | CDK2 | ERBB2 | HRAS | MRE11A | PARP1 | SLC01B1 | VHL |
| ATRX | CDK4 | ERBB3 | IDH1 | MSH2 | PARP2 | SMAD4 | WT1 |
| AURKA | CDK5 | ERBB4 | IDH2 | MSH6 | PDGFRA | SMARCB1 | |
| AURKB | CDK6 | ERCC2 | IGF1R | MTOR | PIK3CA | SMO | |
| AXL | CDK8 | ESR1 | JAK2 | MUTYH | PMS2 | SRC | |
| BCL2 | CDK9 | ETV6 | JAK3 | MYC | PTCH1 | SRSF2 | |
| BRAF | CDKN2A | EZH2 | KDR | MYD88 | PTEN | STK11 | |

TOMA's cloud based data analysis tools:


- Simple
- Complete
- Meaningful



STRATUS



COMPASS



| SEQUENCING PERFORMANCE METRICS - 6 CONCURRENT SAMPLES ON ILLUMINA MISEQ | | | | | | |
|---|-------------|-----------------|----------------------|----------------|-----------------|------------------|
| Mean Coverage | On - Target | Fold Enrichment | Fold 80 Base Penalty | % ROI Bases 2X | % ROI Bases 50X | % ROI Bases 100X |
| > 500 X | 50-80% | 1200-2300 | 1.9 - 3.5 | 99.5% | 98.5% | 98.1% |

The TOMA OS-Seq Cancer Assay is a highly efficient ligation method completely eliminates “whole genome” PCR, to provide a more accurate representation of the original sample in the final sequencing library. TOMA OS-Seq target enrichment is complete within an hour, and enables detection of mutant alleles down to a 2% variant allele frequency (VAF). The TOMA OS-Seq sequencing solution integrated with STRATUS data analysis tool offers a fast, simple approach to generating reliable sequencing data in a short time.

To Order TOMA OS-Seq Reagents
 Call TOMA Customer Service at 877-840-8662 (TOMA)
 Email: orderTOMAOSSeq@tomabio.com

For Research Use Only. Not for use in diagnostic procedures.